Ology Bioservices, Inc.

About Ology Bioservices, Inc.

Ology Bioservices was acquired by National Resilience, Inc. (Resilience) in April of 2021. For more information on available services, please visit the Resilience website at https://resilience.com.

History: Ology Bioservices was founded in 1999 as an integrated biopharmaceutical company with a focus on development and manufacturing as well as having expertise in preclinical and clinical development, formulation optimization, and cGMP manufacturing of biopharmaceutical products and medical devices. From its early beginnings, the company’s growth was fueled through grants and contracts from both industry and several U.S. Government (USG) agencies (NIH, DoD, NCI, BARDA). Today, the company has grown to over 185 employees located in several offices across the U.S. On March 30, 2013, the Department of Defense (DoD) awarded the company and its team of partners and collaborators a contract to provide all of the core services necessary to establish a Medical Countermeasures Advanced Development and Manufacturing (MCM ADM) facility dedicated to meeting the specific needs of the DoD. The 10-year, $400+ million contract had a base period goal for the construction of an 183,000-square-foot, state-of-the-art, BSL-3, single-use facility that the company now occupies and operates. Ology Bio recently developed and acquired proprietary platform technologies that are used in the production of biologic products including proteins, monoclonal antibodies, and vaccines.

Website	https://resilience.com
Employees	11-50 employees View all Ology Bioservices, Inc. employees
Industry	Biotechnology Research
Phone number	386-462-9663
Headquarter	13200 NW Nano Court, Alachua, Florida 32615, US
Founded	1999
Keywords	Gene Therapy, Project Management, Regulatory Compliance, Cell Therapy, Antibodies, Vaccines, Biologics, Biopharmaceutical Manufacturing, Us Government Contracting, Cell Line Development, Viral Vectors, Analytical Method Development, Analytical Method Validation, Oncolytic Viruses, 606, Upstream Process Development, 21 Cfr 600, 21 Cfr 1270 And 1271 (Human Cells, 21 Cfr 210 And 211 (Drugs), Analytical Method Transfer, Iso 9001 (General Quality Systems), Purification Process Development, Tissues And Cellular And Tissue-Based Produc